383 related articles for article (PubMed ID: 19851045)
21. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
Xu H; Robinson GW; Huang J; Lim JY; Zhang H; Bass JK; Broniscer A; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Fisher M; Cohn R; Yamashita T; Teitz T; Zuo J; Onar-Thomas A; Gajjar A; Stewart CF; Yang JJ
Nat Genet; 2015 Mar; 47(3):263-6. PubMed ID: 25665007
[TBL] [Abstract][Full Text] [Related]
22. Ototoxicity.
Rybak LP; Ramkumar V
Kidney Int; 2007 Oct; 72(8):931-5. PubMed ID: 17653135
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.
Schacht J; Talaska AE; Rybak LP
Anat Rec (Hoboken); 2012 Nov; 295(11):1837-50. PubMed ID: 23045231
[TBL] [Abstract][Full Text] [Related]
25. Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.
Hazlitt RA; Min J; Zuo J
J Med Chem; 2018 Jul; 61(13):5512-5524. PubMed ID: 29361217
[TBL] [Abstract][Full Text] [Related]
26. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
[TBL] [Abstract][Full Text] [Related]
27. Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity.
Sheehan K; Sheth S; Mukherjea D; Rybak LP; Ramkumar V
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29608150
[TBL] [Abstract][Full Text] [Related]
28. Nicotinamide adenine dinucleotide: An essential factor in preserving hearing in cisplatin-induced ototoxicity.
Kim HJ; Oh GS; Shen A; Lee SB; Khadka D; Pandit A; Shim H; Yang SH; Cho EY; Song J; Kwak TH; Choe SK; Park R; So HS
Hear Res; 2015 Aug; 326():30-9. PubMed ID: 25891352
[TBL] [Abstract][Full Text] [Related]
29. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
30. Protective effects of 1,2,3-triazole derivative KPR-A020 against cisplatin-induced ototoxicity in murine cochlear cultures.
Kim YR; Jung DJ; Oh SK; Lee T; Lee IK; Lee KY; Kim UK
Int J Pediatr Otorhinolaryngol; 2017 May; 96():59-64. PubMed ID: 28390615
[TBL] [Abstract][Full Text] [Related]
31. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb SJ; Martin K; Abab J; Ratcliffe I; Thornton R; Lineton B; Ellis M; Moody R; Stanton L; Galanopoulou A; Maishman T; Geldart T; Bayne M; Davies J; Lamb C; Popat S; Joffe JK; Nutting C; Chester J; Hartley A; Thomas G; Ottensmeier C; Huddart R; King E
Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
[TBL] [Abstract][Full Text] [Related]
32. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
Viglietta V; Shi F; Hu QY; Ren Y; Keilty J; Wolff H; McCarthy R; Kropp J; Weber P; Soglia J
Invest New Drugs; 2020 Oct; 38(5):1463-1471. PubMed ID: 32157599
[TBL] [Abstract][Full Text] [Related]
33. Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
Sullivan MJ
Cancer; 2009 Dec; 115(24):5623-6. PubMed ID: 19813276
[No Abstract] [Full Text] [Related]
34. Possible protective effect of sertraline against cisplatin-induced ototoxicity: an experimental study.
Ozturk M; Ucar S; Sarı F; Erdogan S; Topdag M; Iseri M
ScientificWorldJournal; 2013; 2013():523480. PubMed ID: 24198723
[TBL] [Abstract][Full Text] [Related]
35. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD010885. PubMed ID: 29975402
[TBL] [Abstract][Full Text] [Related]
36. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
37. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
38. [Genetic background of cisplatin induced ototoxicity].
Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies.
Chattaraj A; Syed MP; Low CA; Owonikoko TK
JCO Oncol Pract; 2023 May; 19(5):278-283. PubMed ID: 36921239
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
